Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Descartes-15 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on Descartes-15, a putative anti-BCMA mRNA chimeric antigen receptor (CAR) T-cell therapy (Mar 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Descartes-15 | Descartes 15|Descartes15 | TNFRSF17 Immune Cell Therapy 27 | Limited information is currently available on Descartes-15, a putative anti-BCMA mRNA chimeric antigen receptor (CAR) T-cell therapy (Mar 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06304636 | Phase I | Descartes-15 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01) | Terminated | USA | 0 |